Integromics, member of the joint venture company, ONCNOSIS-Pharma

ONCNOSIS-PHARMA AIE, a new born Spanish joint venture company has been awarded with one of the first sixteen CENIT grants by the Spanish Government. ONCNOSIS aims to discover novel molecular tools, therapeutic compounds and developing new technological approaches for disease diagnosis, prognosis and treatment in four selected cancers. Associated with ONCNOSIS are 20 publicly -funded centres of research excellence throughout Spain The total budget for the four years project is set to almost 30 Million Euros. Half of that sum will be provided by the Spanish Government through the recently issued CENIT grants. Integromics will be in charge of the LIMS management and development and of the Bioinformatics analysis of the potential markers.

Download this press release as an Adobe PDF document.